Enterprise
FDA Clears AI Software for Coronary Plaque Analysis on CT Scans
Siemens Healthineers' Syngo.CT Coronary Cockpit automates plaque characterization to support treatment planning for coronary artery disease.
Key takeaways
- The FDA granted 510(k) clearance to Syngo.CT Coronary Cockpit, AI software that automates coronary plaque analysis from CCTA scans.
- The software uses AI-based segmentation to characterize plaque quantity and morphology across individual lesions or the entire coronary tree.
- Clinicians can use the tool for enhanced risk stratification and as adjunctive support when planning percutaneous coronary interventions.
- The software operates within Siemens Healthineers' existing Syngo.via imaging platform used in radiology workflows.
- Automated plaque assessment aims to reduce manual analysis time while providing more standardized measurements for clinical decision-making.
FDA Approves Automated Plaque Analysis Tool
The Food and Drug Administration has granted 510(k) clearance to Syngo.CT Coronary Cockpit, artificial intelligence software designed to automate the assessment of coronary plaque from cardiac CT imaging. The software, developed by Siemens Healthineers, operates within the company's Syngo.via imaging platform and analyzes data from coronary computed tomography angiography (CCTA) scans.
The clearance enables clinicians to use the software for enhanced plaque evaluation and as an adjunctive tool when planning percutaneous coronary intervention procedures for patients with coronary artery disease.
How the Technology Works
Syngo.CT Coronary Cockpit employs AI-based segmentation and labeling algorithms to automatically characterize plaque within the coronary arteries. According to Siemens Healthineers, the software can assess both the quantity and morphology of plaque deposits in individual lesions or across the entire coronary tree.
This automated analysis aims to reduce the manual workload typically required for detailed plaque assessment while providing standardized measurements that can inform clinical decision-making. The software integrates directly into existing radiology workflows through the Syngo.via platform, which is already deployed in many healthcare facilities.
Why It Matters
Coronary artery disease remains a leading cause of morbidity and mortality globally, and accurate plaque characterization is essential for risk stratification and treatment planning. Traditional manual analysis of CCTA scans is time-intensive and subject to inter-observer variability. By automating this process with AI, the software could enable more consistent assessments and potentially free clinician time for patient care. The FDA clearance also signals growing regulatory acceptance of AI tools that support—rather than replace—clinical judgment in cardiovascular care.
Clinical Applications
The software targets two primary use cases in coronary artery disease management. First, it supports comprehensive plaque assessment that can help clinicians stratify patient risk more effectively. Second, it provides planning support for percutaneous coronary interventions, procedures in which cardiologists use catheters to open blocked coronary arteries.
"With Syngo.CT Coronary Cockpit, clinicians can obtain advanced insights from a patient's CT scan to support a more comprehensive assessment of cardiac health and better inform treatment decisions, ultimately helping people with coronary artery disease live longer, healthier lives," said Olivia Egan, head of computed tomography at Siemens Healthineers North America.
The clearance adds to a growing portfolio of FDA-approved AI tools for cardiovascular imaging, reflecting the technology's expanding role in radiology and cardiology practice.
These details were first reported by Diagnostic Imaging.